TON - November 2017, Vol 10, No 6

Larotrectinib (LOXO-101), an investigational agent that targets tropomyosin receptor kinase (TRK) fusions, has demonstrated excellent, consistent, and durable antitumor activity in a range of tumor types in adults and children, reported lead investigator David M. Hyman, MD, Chief, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting. Read More ›

It is well known that cancer treatment is often associated with serious adverse side effects, but conventional care is often focused on cure and survival, rather than on a holistic approach to patient care, suggests Nerissa Wood, BSN, RN, OCN, Director, Tulane Comprehensive Cancer Clinic, New Orleans, LA. Read More ›

The optimal use of new agents for the treatment of chronic lymphocytic leukemia (CLL) is still being defined, according to Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center (MSKCC), New York City. Read More ›

“Increasing use of netupitant plus palonosetron would potentially help greater numbers of patients avoid chemotherapy-induced nausea and vomiting, relieving them of the more debilitating complications of anticancer therapy,” said Li Zhang, MD, at the 2017 MASCC Annual Meeting. Read More ›